公开(公告)号：US11980594B2

公开(公告)日：2024-05-14

申请号：US17828983

申请日：2022-05-31

申请人： NOVELWISE PHARMACEUTICAL CORPORATION

发明人： Chung-Yang Huang ,  Chia-Chung Hou

IPC分类号： A61K31/085 ,  A61K31/495 ,  A61P35/00

CPC分类号： A61K31/085 ,  A61K31/495 ,  A61P35/00

摘要： The present invention provides a combination and method for treating a Temozolomide (TMZ)-resistant cancer patient, which comprises a combination of TMZ and an isoform-selective HDAC8 inhibitor, such as BMX at an effective relative ratio to overcome TMZ resistance by enhancing TMZ-mediated cytotoxic effect by downregulating the β-catenin/c-Myc/SOX2 signaling pathway and upregulating WT-p53 mediated MGMT inhibition.